Analyst Price Targets — TEM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 10:38 am | Subbu Nambi | Guggenheim | $65.00 | $57.25 | StreetInsider | Tempus AI Inc (TEM) PT Raised to $65 at Guggenheim |
| May 11, 2026 10:19 am | Yi Chen | H.C. Wainwright | $64.00 | $49.86 | TheFly | Tempus AI price target lowered to $64 from $95 at H.C. Wainwright |
| May 10, 2026 2:07 pm | — | BTIG | $80.00 | $49.86 | TheFly | Tempus AI price target lowered to $80 from $90 at BTIG |
| March 10, 2026 11:21 am | Yi Chen | H.C. Wainwright | $95.00 | $52.03 | StreetInsider | Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright |
| February 25, 2026 2:01 pm | Daniel Arias | Stifel Nicolaus | $60.00 | $53.83 | StreetInsider | Tempus AI Inc (TEM) PT Lowered to $60 at Stifel, Firm Highlights 'Solid' Outlook |
| February 19, 2026 10:00 am | Bradley Bowers | Mizuho Securities | $100.00 | $56.16 | TheFly | Tempus AI initiated with an Outperform at Mizuho |
| February 17, 2026 10:10 am | — | Robert W. Baird | $59.00 | $51.95 | TheFly | Tempus AI initiated with an Outperform at Baird |
| December 22, 2025 12:01 pm | Kyle Mikson | Canaccord Genuity | $80.00 | $64.46 | TheFly | Tempus AI price target lowered to $80 from $95 at Canaccord |
| December 1, 2025 9:34 pm | — | Morgan Stanley | $85.00 | $74.07 | TheFly | Tempus AI assumed with an Overweight at Morgan Stanley |
| November 25, 2025 11:14 am | Mark Massaro | BTIG | $105.00 | $76.06 | StreetInsider | Tempus AI Inc (TEM) PT Raised to $105 at BTIG |
Latest News for TEM
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem,…
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable…
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by…
Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TEM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.